Giredestrant Combination Delays Progression in Advanced Breast Cancer
A phase 3 trial found longer cancer control with giredestrant plus everolimus, with particularly strong results in ESR1-mutated tumors.
Summary
An oral drug combination delayed worsening of advanced breast cancer after earlier hormone treatment stopped working. Researchers randomly assigned 373 patients to giredestrant plus everolimus or standard hormone therapy plus everolimus. Among patients whose tumors carried ESR1 mutations, the median time before cancer progression or death was 10.0 months with giredestrant versus 5.5 months with standard treatment. Across all participants, the corresponding times were 8.8 and 5.5 months. Side effects affected nearly everyone in both groups; mouth sores, diarrhea, and anemia were common. These findings suggest another potential treatment option, particularly for patients with ESR1 mutations, but do not establish longer overall survival. Patients should discuss tumor mutation testing and treatment options with their oncology team. This summary is based on the abstract only.
Detailed Summary
Advanced breast cancer often becomes resistant to treatments that block hormone signaling, leaving patients needing additional options. A new trial tested whether replacing standard hormone therapy with giredestrant, while keeping everolimus, could delay further disease progression. The findings concern cancer treatment, not cancer prevention or lifespan extension in healthy adults.
The phase 3 trial randomly assigned 373 patients with advanced breast cancer that was estrogen receptor positive and HER2 negative. All had experienced progression or recurrence after a CDK4/6 inhibitor plus hormone therapy. Participants received either oral giredestrant plus oral everolimus or standard hormone therapy plus everolimus. Researchers first assessed outcomes in the 207 patients whose tumors carried ESR1 mutations, then in the overall population.
Among patients with ESR1 mutations, median time without cancer progression was 10.0 months with giredestrant versus 5.5 months with standard therapy. The estimated risk of progression or death was 62% lower. Across all participants, median time without progression was 8.8 months versus 5.5 months, with a 44% lower estimated risk. Both comparisons were statistically significant. These results do not establish that patients ultimately lived longer.
Side effects occurred in nearly everyone: 98.9% with giredestrant and 96.8% with standard therapy. Mouth sores, diarrhea, and anemia were common. The findings support discussing this combination and tumor mutation testing with an oncology team after prior treatment fails. However, similar overall side effect rates do not demonstrate equivalent severity, tolerability, or quality of life.
Important uncertainties remain. The trial was open label, and treating investigators assessed progression, which can introduce bias. The abstract does not report overall survival, severe side effects, treatment discontinuations, or detailed outcomes in tumors without ESR1 mutations. Genentech funded the study. This summary is based on the abstract only, so complete methods and results could not be evaluated. Treatment decisions require careful individualized specialist assessment.
Key Findings
- Among 207 patients with ESR1-mutated tumors, median progression-free survival reached 10.0 months with giredestrant versus 5.5 months with standard therapy.
- Across all 373 participants, median progression-free survival was 8.8 versus 5.5 months; the hazard ratio was 0.56.
- Both groups received everolimus, so the trial tested replacing the accompanying hormone therapy, not adding everolimus.
- Side effects affected 98.9% versus 96.8%; similar overall rates do not establish equivalent severity or tolerability.
- Discuss ESR1 mutation testing and treatment sequencing with an oncologist; an overall survival benefit remains unestablished.
Methodology
This phase 3, open-label trial randomized 373 patients 1:1 after progression or recurrence following a CDK4/6 inhibitor plus endocrine therapy. Investigator-assessed progression-free survival was tested hierarchically, first in ESR1-mutated tumors and then overall. The comparator was exemestane, fulvestrant, or tamoxifen plus everolimus.
Study Limitations
This summary is based on the abstract only, without access to the full methods or results. The open-label design and investigator-assessed progression introduce potential assessment bias; overall survival, quality of life, severe adverse events, and discontinuations are not reported in the abstract. Genentech funded the trial, and detailed outcomes for tumors without ESR1 mutations are unavailable here.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: